# Home electrocardiogram telemonitoring for post-acute myocardial infarction care: a randomized controlled trial

## TL;DR

A study tested a home ECG device for heart attack patients but found no overall benefit, though proper use reduced unnecessary emergency visits.

## Contribution

This is the first US randomized trial to evaluate a 12-lead ECG telemonitoring device for post-AMI care.

## Key findings

- No significant difference in ED visits or readmissions between groups in intention-to-treat analysis.
- Proper device use reduced inappropriate ED visits and increased appropriate ones in per-protocol analysis.
- One patient survived cardiac arrest after following device alerts to seek emergency care.

## Abstract

Acute myocardial infarction (AMI) patients face a substantial risk of cardiovascular events and rehospitalization. The impact of the SmartHeart 12-lead electrocardiogram (ECG) telemedicine device on healthcare utilization has not been tested in a US randomized trial.

Patients with AMI were randomized at discharge to standard of care without (control group) or with the SmartHeart 12-lead ECG device (intervention group). The primary endpoint was the rate of emergency department (ED) visits, hospital readmissions, and any cardiovascular testing from discharge to 90 days of follow-up. The primary endpoint was reached in 57 (59%) patients in the control group and 53 (63%) patients in the intervention group (P = 0.61). However, in the intervention group, only 30% of patients complied with two follow-up training SmartHeart 12-lead ECG transmissions after discharge, and only 24% used the device thereafter. Among device users, ED presentations were lower in the intervention group than in the control group (8.0% vs. 29%, P = 0.04). In all patients advised to present to the ED upon device use (38%), a clinically relevant cardiovascular diagnosis was made. One patient survived a ventricular fibrillation cardiac arrest as advised to present to ED urgently after device use.

In this US-based RCT, there were no significant differences in the primary outcome in the intention-to-treat analysis. However, according to per-protocol analysis, proper use of the SmartHeart ECG device with 24/7 telemedicine support reduced inappropriate and increased appropriate ED presentations after hospitalization for AMI.

Graphical AbstractFor image description, please refer to the figure legend and surrounding text.